Please Wait.....
Report
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Industry Report I 2022-07-29 I 138 Pages I Global Markets Direct
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.
Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 42, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 3 molecules, respectively.
Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Klebsiella pneumoniae Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Klebsiella pneumoniae Infections - Drug Profiles
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Jul 07, 2020: Data published in Ebiomedicine validates novel scientific approach that disarms bacterial defenses to treat or prevent life-threatening infections
Sep 05, 2019: Summit presented in vivo proof of concept data for targeted Enterobacteriaceae antibiotics at ASM/ESCMID Conference
Aug 27, 2019: Vaccine against deadly superbug Klebsiella effective in mice
Aug 20, 2019: Vaxxilon receives grant to develop new prophylactic vaccine
Jul 02, 2019: Appili Therapeutics signs $3M USD grant contract with the United States Department of Defense to develop antibiotics that target superbugs
Apr 03, 2019: Summit's pipeline expands with series of new mechanism antibiotics targeting Enterobacteriaceae
May 07, 2018: Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
Apr 17, 2018: Arsanis to Present Abstract On ASN300 At The 28th European Congress of Clinical Microbiology And Infectious Diseases
Nov 07, 2017: Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria
Sep 30, 2017: Development of a negamycin analogue targeting the translational machinery in gram-negative drug-resistant pathogens for the treatment of Infections
Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections
Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, 2022
Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Alterity Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Bioversys AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by CHO Pharma Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Clarametyx Biosciences Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, 2022
Klebsiella pneumoniae Infections - Pipeline by Dong-A ST Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by GSK plc, 2022
Klebsiella pneumoniae Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Infextious Therapeutic, 2022
Klebsiella pneumoniae Infections - Pipeline by LimmaTech Biologics AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Linnaeus Bioscience Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Mikrobiomik Healthcare Company SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Nektr Technologies Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, 2022
Klebsiella pneumoniae Infections - Pipeline by Novabiotics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, 2022
Klebsiella pneumoniae Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Planet Biotechnology Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Seres Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spexis AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Techulon Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Centre, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..1)
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..2)
Klebsiella pneumoniae Infections - Discontinued Products, 2022
List of Figures
Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security